Frequency and prognostic significant of CYP3A4-A-290G polymorphism in acute myeloid leukemia  by Ali, Gamal T. et al.
Journal of Advanced Research (2014) 5, 657–661Cairo University
Journal of Advanced ResearchORIGINAL ARTICLEFrequency and prognostic signiﬁcant of CYP3A4-
A-290G polymorphism in acute myeloid leukemia* Corresponding author. Tel.: +20 1006231077.
E-mail address: nevin_elazhary@hotmail.com (N.M. Al-azhary).
Peer review under responsibility of Cairo University.
Production and hosting by Elsevier
2090-1232 ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.
http://dx.doi.org/10.1016/j.jare.2013.10.002Gamal T. Ali a, Nevin M. Al-azhary a,*, Doha A. Mokhtar ba Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
b Clinical Pathology Department, Faculty of Medicine, Cairo University, Cairo, EgyptA R T I C L E I N F O A B S T R A C TArticle history:
Received 26 July 2013
Received in revised form 23 October
2013
Accepted 24 October 2013
Available online 31 October 2013
Keywords:
CYP3A4-A
290G
AML
Prognosis
PCR/RFLPCytochrome P450 3A4 (CYP3A4) is the most plentiful cytochrome P450 in adult human liver
and small intestine and is responsible for detoxiﬁcation of more than 50% of drugs in addition
to the metabolic deactivation and metabolism of many carcinogens. Polymorphism of CYP3
A4-A-290G considered the only allele that appears to stimulate CYP3A4 expression and has
been associated with a number of clinical phenotypes, including prostate cancer, breast cancer,
leukemia and the early onset of puberty. In this study, we analyzed the presence of CYP3A4-A-
290G polymorphism in 77 newly diagnosed AML cases and 72 healthy control using PCR/
RFLP aiming to show CYP3A4-A-290G polymorphism pattern in acute myeloid leukemia
patients, and its role in disease severity and progression. A highly statistically signiﬁcant
difference was found between the control and AML groups as regards the heterozygous
genotype (p-value = 0.002) and increases the risk of AML 11.4-fold. Also there was a highly
signiﬁcant difference between the control and AML patients regarding variant allele (G in
AG and GG genotypes) (p-value 0.001) and increases the risk of AML 19-fold. No statistically
signiﬁcant association found between the CYP3A4-A-290G polymorphism and different clinical
or laboratory parameters as well as an initial response to treatment, overall survival and the
disease free survival. We concluded that CYP3A4-A-290G polymorphism is a genotypic factor
that increases the CYP3A4 enzymatic activity and increases the risk of AML by 18.9-fold.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Acute myeloid leukemia is the most common acute leukemia
mostly affecting adults, characterized by the rapid growth ofabnormal white blood cells in the bone marrow and impaired
production of normal blood cells [1]. The mechanisms for
AML genesis are still rarely understood. Several genetic poly-
morphisms have been determined as possible risk factors for
leukemia [2].
Recent evidence indicates that enzymes involved in carcin-
ogen activation or deactivation as well as their encoding genes,
might play critical roles in determining individual susceptibility
to cancers. Polymorphisms in these genes encoding the en-
zymes, possibly by altering their functions, could affect carcin-
ogen activation (either increase or decrease) and modulating
DNA repair processes [3]. Cytochrome P450 enzymes are
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and all other xenobiotics [4].
The CYP3A enzymes are involved in the metabolism of
more than 50% of all drugs presently on the market, and they
contribute in the metabolic activation and metabolism of var-
ious carcinogens such as aﬂatoxin B and many anticancer
drugs. Cytochrome P450 3A4 is found to be the most plentiful
cytochrome P450 in adult human liver and small intestine [5].
Genetic polymorphisms within the drug-metabolizing en-
zymes are quite general and may participate to the risk of
developing cancers. CYP3A4*1B is considered the only allele
that appears to inﬂuence the CYP3A4 expression [6].
In this study, the presence of polymorphism was analyzed
by a molecular PCR-RFLP technique in 77 newly diagnosed
AML cases and 72 age and sex comparable healthy controls,
to estimate the risk of AML with this polymorphism and its
prognostic signiﬁcance in AML patients.Patients and methods
The study was approved by the Cairo University Hospital
Research Ethics Committee (REC) and informed consent was
obtained from each patient before starting the data collection.
The study included 77 newly diagnosed AML patients which
presented to the Adult and Pediatric Oncology Department,
National Cancer Institute (NCI), Cairo University in the per-
iod between April 2010 and October 2011. Diagnosis was per-
formed according to clinical, morphological, cytochemical and
Flow Cytometric analysis. The recruited patients comprised of
43 males and 34 females between the age of 4 and 83 years with
a median of 35 years and control group composed of 72 indi-
vidual comprising 53 male and 19 female was randomly se-
lected from blood donors; their ages ranged from 19 to
53 years with a median age 31.5 years.
With respect to all patients’ conﬁdentiality, they were repre-
sented by code numbers. All patients were subjected to a pre-
cise history taking, clinical examination and routine laboratory
investigations including complete blood picture, functions of
both liver and kidney. For each patient, 10 ml of blood was
collected in a sterile heparinized vacutainer. Response to
induction therapy was assessed between days 14, and 28 after
induction treatment, and follow up of cases was done for a per-
iod of at least 6 months to calculate their disease free survival
and overall survival. Complete response was deﬁned in accor-
dance with standard criteria [7], which required an absolute
neutrophils count of 1.5 · 109/L or more, a platelet count of
100 · 109/L or more, no blasts in PB, BM cellularity more
than 20%, no auer rods, less than 5% BM blasts and no extra
medullary leukemia.
The CYP3A4-A-290G polymorphism was determined using
a PCR/RFLP method [8], and Genomic DNA used was ex-
tracted from lymphocytes using QIAamp DNA Mini isolation
kit (QIAGEN).
The primers used were as follows Fwd: GGA CAG CCA
TAG AGA CAA GGG CC Rev: TCA CTG ACC TCC
TTT GAG TTC ATA. PCR was performed in 200 ng of geno-
mic DNA, 0.5 lmol/L of primers Fwd and Rev, 200 lmol/L
dNTPs, 10 mmol/L Tris–HCl (pH 8.3), 2.5 mmol/L MgCl2,
50 mmol/L KCl and 0.5 U Hotstart DNA polymerase (Qia-
gen). After denaturation for 10 min at 95 C, 35 cycles
of 45 s at 95 C, 45 s at 59 C, and 1 min at 72 C, the lastelongation step was extended to 7 min. Digestion of the PCR
product with 10U of Msp1 restriction enzyme in a ﬁnal volume
of 20 ll incubated at 37 C for overnight. The presence of the
A to G polymorphism introduces the restriction site
(50CCGG30) recognized by the Msp1 restriction enzyme
(New England Biolabs Inc., Ipswich, MA). The result is either
retention of a 165-base pair (bp) product or complete digestion
to 142-bp and 23-bp fragments corresponding to individuals
homozygous for the A (wild type) or G (variant) alleles respec-
tively. The presence of both the 165- and 142-bp fragments
corresponded to heterozygous individuals. The polymorphism
was detected on a 3% agarose gel (see Fig. 1).
Statistical analysis
Data were analyzed with SPSSwin statistical package version
20 (SPSS Inc., Chicago, IL). Numerical data were expressed
as mean and standard deviation or median and range as
appropriate. Qualitative data were expressed as frequency
and percentage. Chi-square test (Fisher’s exact test) was used
to examine the relationship between qualitative variables. Sur-
vival analysis was performed using the Kaplan–Meier method
and comparison between two survival curves was made using
the log-rank test. Logistic regression was used for calculation
of odds ratio (OR) with it 95% conﬁdence interval (CI) for risk
estimation. A p-value < 0.05 was considered signiﬁcant.
Results and discussion
In our study we analyzed the presence of CYP3A4-A-290G
polymorphism by molecular PCR-RFLP technique in 77 new-
ly diagnosed AML cases, and 72 age and sex comparable
healthy controls (statistical analysis regarding the age and gen-
der of studied population is shown in Table 1 and laboratory
ﬁndings in AML patients are shown in Table 2). The cases
were examined for the CYP3A4-A-290G polymorphism, and
followed up for 6 months regarding disease outcome and over-
all survival (Initial response to induction therapy among AML
patients at 28 days is shown in Table 3).
We found that the heterozygous genotype (AG) was more
frequent in AML cases (21.6%) than the control group
(2.8%), with statistically signiﬁcant difference (p-va-
lue = 0.002, OR = 11.4, 95%CI = 2.513–51.974), the homo-
zygous genotype (GG) also more frequent in AML cases
(12.2%) than control group (0%), however this difference
was not statistically signiﬁcant (p-value = 0.999). As regards
the variant allele (G in AG and GG genotypes), we found that
it was more frequent in AML cases (33.8%) than in the control
group (2.8%) with statistically signiﬁcant difference (p-va-
lue = 0.001, OR = 18.9, 95%CI = 4.041–78.903) as shown
in Table 4.
In agreement with our data, Voso et al. [8] in a case-control
study including 160 cases of AML and 162 matched controls,
reported that a signiﬁcantly higher prevalence of the polymor-
phic variants CYP3A4-A-290G genes in AML cases, when
compared with controls (9.4% vs. 3.1%, P= 0.04) increasing
the risk of AML 3.2-fold, (95% CI: 1.1–11.5).
However, Bolufer et al. [9] reported in a case-control study
including 443 patients with acute leukemia (302 with AML and
141 with ALL) and 454 control volunteers that the frequency
of CYP3A4-A-290G variants in AML cases, compared with
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• Lane 1:  50 bp ladder 
• Lane 2,3,5,6,7,8,10: Wild type (A) 
showing one band at 165 bp 
• Lane 9: Heterozygous variant (AG) 
showing bands at 165,142 bp 
• Lane 4: -ve for PCR 
Fig. 1 PCR-RFLP detection of CYP3A4-A-290G.
Table 1 Statistical analysis regarding the age and gender of the studied population.
Group Age Sex
Mean ± SD Median (range) Male no. % Female no. %
Cases (no. 77) 38.2 ± 17.5 35(4–83) 43 (55.8%) 34 (44.2%)
Control (no. 72) 32 ± 9.2 31.5(19–53) 53 (73.6%) 19 (26.4%)
Table 2 Statistical analysis of laboratory ﬁndings in AML
patients (n= 77).
Mean ± SD Median (range)
PB Tlc · 109/L 35.6 ± 35.356 27.3 (0.2–180)
PB Hb gm/dl 7.4 ± 2 7.2 (3–13.9)
PB Plt · 109/L 45.9 ± 40.64 37 (2–271)
PB Bl% 38 ± 28 32 (0–90)
BM Bl% 56 ± 27 65 (20–92)
PB: peripheral blood, BM: bone marrow, TLC: total leucocytic
count, SD: standard deviation, Plt: platelet, Bl: blast.
Table 3 Initial response to induction therapy among AML
patients at (28 days) (n = 77).
Frequency Percent
CR 31 40.3
NO CR 6 7.8
DEAD 40 51.9
CR: complete remission.
Prognosis of CYP3A4-A-290G polymorphism in AML 659controls was (6.8% vs. 8.1%) without any statistically signiﬁ-
cant difference. Also, the frequency CYP3A4-A-290G variant
in ALL cases, compared with controls was (5.5% vs. 8.1%),
without any statistically signiﬁcant difference.
Blanco et al. [10] compared the genotype frequencies for the
CYP3A4-A-290G polymorphism in 224 children with ALL
who did not develop t-AML (controls), and in 53 children with
ALL who did develop a complication. They found no differ-
ences in the CYP3A4-A-290G allele distribution between
ALL controls and t-AML patients in whites (6.6% vs. 9.8%,
P= 0.339), blacks (93.8% vs. 87.5%, P= 0.498) or Hispanics
(39.1% vs. 25.0%, P= 0.523). Suggesting that there is no
association between the CYP3A4-A-290G polymorphism and
the risk of t-AML in children treated for ALL.Pakakasama et al. [11] also analyzed 107 children with ALL
and 320 healthy controls for CYP3A4-A-290G polymorphism,
and they found the very low frequency of CYP3A4-A-290G al-
lele which was 0.8% and 0.9% in ALL and controls showing
no statistically difference between patients and controls.
Kim et al. [12] analyzed 100 ALL pediatric patients for the
CYP3A4-A-290G polymorphism; they found that the distribu-
tion of the variant allele was 0%.
Naoe et al. [13] analyzed 58 patients with t-AML/t-MDS
and 150 Japanese healthy individuals for the CYP3A4-A-
290G polymorphism; they found that all had a wild type geno-
type except one case only had a heterogenous genotype of the
variant allele, which indicates a very low frequency or a lack of
CYP3A4-A-290G polymorphism in Japanese persons.
This controversy in the results is likely due to the diverse
ethnic group, the different sample size and the exposure to dif-
ferent carcinogens in different environments (gene environ-
mental interaction). This could also explain by what was
previously stated that the CYP3A4*1B variant has a contro-
versial functional role, where Felix et al. [14] reported that
the CYP3A4 wild genotype may increase production of poten-
tially DNA-damaging reactive intermediates and the variant
may decrease production of potentially DNA-damaging reac-
tive intermediate. While Voso et al. [8] mentioned that
CYP3A4-A-290G polymorphism is believed to cause an in-
crease in enzymatic activity, and so increase bioactivation of
several chemical carcinogens associated with cancers.
Considering the prevalence of CYP3A4-A-290G polymor-
phism in normal the Egyptian population, we found that the
frequency of heterozygous and homozygous genotypes was
2.8% and 0% respectively in our control group, also shown
in Table 4.
In our study, there was no signiﬁcant value in CYP3A4-A-
290G genotypes in relation to the initial response at d28 (CR
or unfavorable response) (p-value = 0.757) shown in Table 5
and also no signiﬁcant value in relation to the overall survival
(p-value = 0.380 & for variant allele p-value = 0.459) is
shown in Table 6 and Figs. 2 and 3. [Valid numbers 74 as there
Table 4 Comparison between the frequency of CYP3A4-A-290G types in AML vs. control groups.
Group p-Value OR 95%CI
Control (no. = 72) AML (no. = 74)
Wild type (AA) Count 70 49 Ref
% Within group 97.2% 66.2%
Heterozygous (AG) Count 2 16 0.002 11.429 2.513–51.974
% Within group 2.8% 21.6%
Homozygous (GG) Count 0 9 0.999
% Within group 0% 12.2%
Variant allel (AG+GG) Count 2 25 0.001 18.857 4.041–78.903
% Within group 2.8% 33.8%
p-Value < 0.05 was considered signiﬁcant.
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Fig. 2 Kaplan Meier curve of overall survival for CYP3A4-
290G genotypes (AA, AG, GG) groups.
660 G.T. Ali et al.were 3 cases failed to get ampliﬁed in the PCR-RFLP
technique].
In agreement with our results Barragan et al. [15] genotyped
153 patients diagnosed with de novo AML to clarify the inﬂu-
ence of the genetic CYP3A4-A-290G polymorphism on disease
outcome, and they found no relationship between the
CYP3A4-A-290G polymorphism and the disease outcome.
This is nearly matched with the previously reported fre-
quency of these genotypes in Caucasians reported by Voso
et al. [8] (3.1–0%), Spanish reported by Bolufer et al. [9]
(8.1–0%) and European done by Garsa et al. [16] (7.5–0%).
In contrast to our study the frequency of these genotypes
was (40–39.2%) in African American reported by Zeigler-
Johnson et al. [17] (36–51%) in Ghanaians by Tayeb et al.
[18], and (2.9–65.1%) in Senegalese analyze by Zeigler-
Johnson et al. [17], while they were not detected at all (0%)
in Taiwanese, Chinese and Japanese which was reported by
Walker et al. [19].
Conclusions
It could be concluded that, CYP3A4-A-290G polymorphism is
a genotypic factor that increases the CYP3A4 enzymatic activ-
ity and increases the risk of AML by 18.9-fold. We need a largeTable 5 CYP3A4-A-290G genotypes in relation to initial response at d28 (n= 74).
GG no. (%) AG no. (%) Variant allele no. (%) Wild type no. (%) p-Value
CR 5 (55.6) 5 (63.2) 10 (33.3) 20 (66.7) 0.757
NO CR 1 (11.1) 0 (0) 1 (16.7) 5 (83.3)
DEAD 3 (33.3) 11 (36.8) 14 (36.8) 24 (63.2)
p-Value > 0.05 which was considered not signiﬁcant – chi-square test was used.
Table 6 CYP3A4-A-290G genotypes in relation to the overall survival (n= 74).
No. Overall cumulative survival (%) Median survival (month) 95% Conﬁdence interval p-Value
Wild AA 49 42.86 3.52 0.00–8.57 0.380
Hetero AG 16 31.25 0.66 0.21–1.11
Homo GG 9 44.44 1.51 1.22–1.80
Variant 25 36 0.82 0.28–1.36 0.459
p-Value > 0.05 which was considered not signiﬁcant log-rank test was used.
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Fig. 3 Kaplan Meier curve of overall survival as regards patients
carrying the variant G allele.
Prognosis of CYP3A4-A-290G polymorphism in AML 661study sample to conﬁrm that CYP3A4-A-290G polymorphism
is a predisposing host genetic factor to AML.
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